Conjupro Biotherapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding, Subsidiary
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.conjuprobio.com
Clinical Trials
8
Active:1
Completed:1
Trial Phases
2 Phases
Phase 1:7
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 1
7 (87.5%)Phase 2
1 (12.5%)A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Conjupro Biotherapeutics, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT05948865
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, United States
Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Conjupro Biotherapeutics, Inc.
- Registration Number
- NCT05043987
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Conjupro Biotherapeutics, Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT04931823
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸Yale University School of Medicine - Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
Dose Escalation and Expansion Study of CPO107 for Patients with Advanced CD20-positive Non-Hodgkins Lymphoma
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Conjupro Biotherapeutics, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT04853329
- Locations
- 🇺🇸
Novant Health, Charlotte, North Carolina, United States
NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy
Phase 2
Withdrawn
- Conditions
- Peripheral NeuropathyBreast Cancer
- Interventions
- Drug: PlaceboDrug: NBP Softgel Capsules
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Conjupro Biotherapeutics, Inc.
- Registration Number
- NCT04675450
- Prev
- 1
- 2
- Next
News
No news found